Table 1 Baseline clinical characteristics of HIV-HL patients
Characteristic | Total (n = 19)/N(%) |
|---|---|
Demographics | |
Male, n | 17(89.5) |
Age, years, mean (range) | 43(22–74) |
≤60 | 18(94.7) |
HIV factors | |
HIV-transmission category | |
MSM (Men having sex with men) | 10(52.6) |
Heterosexuals | 9(47.4) |
Concomitant HIV and lymphoma diagnosis | 7(36.8) |
HIV viral load, copies/mL, median (range) | 50 (0–87,202) |
Undetectable patients | 5(26.3) |
CD4 count, ×106 /L, median (range) | 110(24–434) |
<50 × 106 /L | 5(26.3) |
(50–200)×106 /L | 8(42.1) |
>200 × 106 /L | 6(31.6) |
CD4/CD8, below normal | 12(63.2) |
Concurrent Epstein-Barr virus | 12(63.2) |
Concurrent hepatitis B virus | 1(5.3) |
ART | 22(100) |
No ART at diagnosis | 7(36.8) |
Previous ART resistance | 12(63.2) |
Lymphoma factors | |
Lymphoma subtype | |
Mixed cellularity | 17(89.5) |
Lymphocyte predominant | 2(10.5) |
ECOG PS > 1 | 5(26.3) |
Stage 3–4 | 19(100) |
Elevated LDH | 8(42.1) |
aaIPI 2–3 | 14(73.7) |
CNS/leptomeningeal involvement | 1(5.3) |
Bone marrow involvement | 5(26.3) |
Bulky disease | 5(26.3) |
B symptoms | 16(84.2) |
Treatment factors | |
Chemotherapy regimen | |
ABVD | 19(100) |
CNS prophylaxis | 1(5.3) |
ART use | 19(100) |
Concurrent ART with chemotherapy | 19(100) |